Epizyme to Report Second Quarter 2016 Financial Results on August 8, 2016 and Participate in Upcoming Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, announced today that management will host a conference call and audio webcast on Monday, August 8, 2016, at 8:30 a.m. Eastern Time to report business highlights and progress against the company’s multi-year vision, along with second quarter 2016 financial results.

To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 53968160. The webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.epizyme.com.

Wedbush PacGrow Healthcare Conference
In addition, the company will be participating in the 2016 Wedbush PacGrow Healthcare Conference. The presentation will be webcast and take place on August 16, 2016 at 8:35 a.m. Eastern Time. A replay of the webcast can be accessed in the Investor Relations section of the Company’s website at www.epizyme.com.

About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics for people with cancer. Epizyme has built a proprietary product platform to create small molecule inhibitors of chromatin modifying proteins (CMPs), such as histone methyltransferases (HMTs). CMPs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of CMPs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients. For more information, visit www.epizyme.com.

Investors: Monique Allaire, 617-895-9511 THRUST Investor Relations Monique@thrustir.com Media: Michael Lampe, 484-575-5040 Scient Public Relations michael@scientpr.com

Source:Epizyme, Inc.